ResearchPod Summary
This module outlines the pharmacology of diverse cancer immunotherapy classes, including checkpoint inhibitors, bispecific T-cell engagers, anticancer vaccines, CAR T-cell therapy, and cytokines. Checkpoint inhibitors (such as anti-PD-1, anti-PD-L1, and anti-CTLA-4 agents) function by removing inhibitory signals on T cells, thereby enhancing the immune system's ability to identify and destroy tumor cells. The module also covers more complex therapies like CAR T-cell therapy and tumor-infiltrating lymphocyte (TIL) therapy, which involve the infusion of genetically modified or ex-vivo expanded autologous immune cells to target specific cancer antigens.
A critical focus of this material is the identification and management of immune-related adverse events (irAEs). Because these agents activate the immune system, they can trigger systemic inflammatory responses in various organ systems, including the skin, gastrointestinal tract, liver, and endocrine glands. The module emphasizes early recognition and the use of corticosteroids as the primary management strategy for most irAEs, with additional immunosuppressive agents required in refractory cases.
Beyond general irAEs, the text provides specific protocols for handling unique toxicities associated with newer modalities. For CAR T-cell therapies and bispecific T-cell engagers, the module details the management of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS). Key supportive measures include the use of tocilizumab for CRS and rigorous neurological monitoring for ICANS, highlighting the necessity for standardized order sets and highly trained multidisciplinary teams.
Immunotherapy has fundamentally changed cancer treatment, but its success depends on the provider's ability to safely administer these agents. Pharmacists and clinicians must balance the potent antitumor efficacy of these drugs against the potential for severe, sometimes life-threatening, immune-mediated toxicities. Understanding the distinct pharmacological properties, monitoring requirements, and intervention thresholds presented in this module is essential for mitigating risks and optimizing patient outcomes.
AI-generated third-party summary by ResearchPod. Not official content or an endorsement by the paper authors or affiliated organizations.